Alliance for Biosecurity

Strengthen Our Voice, and Yours

BECOME AN ALLIANCE MEMBER

"For more than a decade, the Alliance for Biosecurity has proven vital to ensuring that MCM public-private partnerships are sustained and remain strong. Speaking together as a single industry voice grows the opportunity for our message to be heard, understood, and acted upon."

- Jack Kingston, Alliance Secretariat
Former U.S. Representative

Advancing America's biosecurity through partnership, preparedness, and policy

The Alliance is a coalition of biopharmaceutical companies and laboratory partners that promotes a strong public-private partnership to ensure MCMs are available to protect public health and enhance national health security. The Alliance advocates for public policies and funding to support the rapid development, production, stockpiling, and distribution of critically needed MCMs.

Alliance for Biosecurity Priorities

ADVOCATE for sustained, bipartisan federal investment in the programs that strengthen America's biodefense: BARDA, ASPR, Project BioShield, Pandemic Influenza, the SNS, and more.

ENHANCE public-private partnerships that accelerate innovation, streamline procurement, and close readiness gaps across the CBRN threat landscape.

SUPPORT the development and stockpiling of next-generation countermeasures — from antibacterials and antivirals to urgently needed antifungal agents.

PROMOTE a coordinated, forward-looking national biodefense strategy aligned with Executive Order 14155 and the President's call for a unified biosecurity framework.

ENGAGE with Congress, the Administration, and federal agencies to shape a forward-looking national biodefense strategy that aligns with President Trump's call for a unified biosecurity framework.

EDUCATE policymakers, the press, and the public on the importance of sustained preparedness and the vital role of domestic MCM development.

Alliance Members

GSK
JUBILANT HOLLISTERSTIER
SIGA Human BioArmor
EMERGENT™
Elusys THERAPEUTICS, INC.
SCYNEXIS
bioCryst
Baxter
INDIVIOR

MEMBERSHIP FEES: $2,300 PER COMPANY PER MONTH

- Fees have remained unchanged since 2017
- Biannual Alliance Board meetings with industry & government leaders
- Regular engagement with senior officials from HHS, ASPR, BARDA, and House & Senate leadership
- Quarterly meetings with key members of Congress and the Administration
- Twice-monthly government relations updates and strategic coordination calls
- Ongoing public affairs and media engagement to advance Alliance priorities

Contact to join or get more info:
info@allianceforbiosecurity.com
202.457.6331
@AllianceCBRN
www.allianceforbiosecurity.com

Collaboration with Government

The Alliance is a longstanding partner of the U.S. government and several federal agencies in combatting deadly threats, supporting our nation's readiness, safety, and response efforts, while ensuring that the U.S. remains prepared to address growing CBRN threats.

Congress must prioritize consistent support for the SNS, ASPR, BARDA, Project BioShield, Pandemic Influenza, and other critical programs to bolster U.S. biodefense preparedness. For Fiscal Year 2026, the Alliance has requested $1.4 billion for BARDA advanced research and development, $1 billion for Project BioShield, $1.588 billion for the Strategic National Stockpile, and $410 million for Pandemic Influenza Preparedness in light of the ongoing H5N1 avian influenza outbreak. These investments sustain a BARDA pipeline of more than 200 candidate medical countermeasures. While these programs have benefited from past congressional support, historic funding levels have not kept pace with evolving threats—resulting in persistent shortfalls that hinder readiness and response capacity. Sustained, increased investment is essential to close these gaps and ensure preparedness.

The government cannot do this alone. Consistent funding and robust public-private collaboration will safeguard public health, reinforce national resilience, and ensure the availability of critical MCMs.

By maintaining and expanding existing contracts for critical MCMs, government can support ongoing industry research and development while leveraging industry expertise to streamline supply chains and maintain stockpiles for rapid response. This was the case in 2020 when Alliance member companies leveraged their robust domestic manufacturing capabilities to implement historic, life-saving efforts through Operation Warp Speed. Today, funding shortfalls have left the U.S. Government with diminished capabilities to address biological threats compared to the resources and readiness seen during Operation Warp Speed – underscoring the importance of additional investment in this enterprise. In 2025, Alliance Co-Chair Christopher Frech testified before the House Appropriations Subcommittee on Labor, Health and Human Services in support of these investments, and the Alliance endorsed bipartisan legislation, H.R. 2707, to modernize the nation's anthrax preparedness strategy and strengthen coordination between HHS and the Department of Defense.

NEXT GENERATION BIODEFENSE

The Trump Administration's health policy decisions—such as the withdrawal from the WHO—highlight the urgent need for a strong domestic biodefense and a coordinated biosecurity framework across Congress, federal agencies, and the private sector.

- Enhancing cross-sector coordination for rapid MCM development.
- Bolstering supply chain resilience through U.S. biomanufacturing.
- Incentivizing public-private partnerships through advanced purchase agreements.
- Fast-tracking emergency MCM regulatory approvals.
- Reauthorizing the *Pandemic and All-Hazards Preparedness Act* (PAHPA).
- Sustaining federal investment in MCM based on Material Threat Determinations (MTD).
- Ensuring the U.S. national security strategy includes biodefense and CBRN threats identified in the 2025 *Annual Threat Assessment of the U.S. Intelligence Community*.

As the CBRN threat landscape continues to evolve, sustained collaboration between federal agencies and private industry is vital for a robust U.S. national security policy.

Alliance for Biosecurity members remain committed to supporting these efforts as trusted partners and resources to Congress, federal agencies, and the American public.

Alliance for Biosecurity